Imatinib Grindeks (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing phosphorylation of downstream signaling proteins, it stops malignant cell proliferation, induces apoptosis, and reduces tumor angiogenesis, leading to disease control in the approved indications.

The dose of Imatinib Grindeks is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here; the prescriber determines the appropriate dosing schedule.

Safety data for Imatinib during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and treatment options with their healthcare provider.

To request Imatinib Grindeks, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for CML and Ph+ ALL. Newer agents such as dasatinib or nilotinib may offer faster molecular responses but have different safety profiles. Choice of therapy depends on disease characteristics, patient comorbidities, and physician judgment.

Imatinib Grindeks should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Imatinib Grindeks is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing instructions provided by their prescriber and not crush or split the tablet unless directed.

The most serious adverse events include severe neutropenia or thrombocytopenia, hepatotoxicity, cardiac failure, and pulmonary arterial hypertension. Patients should be monitored regularly for blood‑count abnormalities, liver‑function changes, and cardiac symptoms, and any severe reaction should prompt immediate medical evaluation.

Imatinib Grindeks is contraindicated in individuals with known hypersensitivity to Imatinib or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those taking medications that may cause dangerous drug‑drug interactions. The prescriber should assess suitability before initiating therapy.